Please login to the form below

Not currently logged in
Email:
Password:

MedImmune

This page shows the latest MedImmune news and features for those working in and with pharma, biotech and healthcare.

Sanofi buys into AZ drug for preventing RSV infections

Sanofi buys into AZ drug for preventing RSV infections

Sanofi is paying 120m upfront for a share in a respiratory syncytial virus (RSV) drug in development at AstraZeneca's MedImmune unit. ... As a global leader in the paediatric vaccine industry, this deal with MedImmune therefore makes perfect sense for

Latest news

More from news
Approximately 15 fully matching, plus 95 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    Deal Watch March 2017. Sanofi, MedImmune, AstraZeneca, Astellas, Novartis and more feature in this month's pharma deals round-up. ... Headline. $m. AstraZeneca/ MedImmune. Sanofi Pasteur. Joint Development. MEDI8897; monoclonal antibody to respiratory

  • Deal Watch October 2016 Deal Watch October 2016

    Licensee / Acquirer. Deal type. Product /technology. Headline $m. Medimmune / AstraZeneca (UK).

  • Deal Watch February 2016 Deal Watch February 2016

    We have seen this for several of the large pharma firms and this month AstraZeneca licensed an antibody developed by MedImmune to start-up company Corvidia Therapeutics concurrently with Corvidia's ... acquisition - corporate. 29.35. AstraZeneca/

  • Pharma deals in August 2015 Pharma deals in August 2015

    MedImmune has paid $27.5m upfront, with a further $700m in milestones and double digit tiered royalties. ... Acquisition ‐ company. 847. Inovio. AZ/Medimmune. INO‐ 3112 vaccine in P1/2 for cervical and head &neck cancer.

  • Pharma deals in February 2015 Pharma deals in February 2015

    platform. This has been rewarded over the years by a string of research alliances with companies including AstraZeneca, MedImmune, Novartis, Takeda and Cubist (now Merck &Co), as well as an extensive

More from intelligence
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest appointments

  • AZ and Medimmune bolsters immuno-oncology leadership AZ and Medimmune bolsters immuno-oncology leadership

    AZ and Medimmune bolsters immuno-oncology leadership. Dr Jean-Charles Soria and Dr Geoffrey Kim join the company. ... AstraZeneca and its global biologics research and development arm MedImmune, has appointed Dr Geoffrey Kim and Dr Jean-Charles Soria,

  • AstraZeneca appoints head of oncology AstraZeneca appoints head of oncology

    AstraZeneca appoints head of oncology. Dr Jamie Freedman joins from AZ subsidiary MedImmune. ... Dr Freedman moves to AstraZeneca from its subsidiary MedImmune, where he was senior vice president of global clinical development, with responsibility for

  • Nanobiotix strengthens US leadership team Nanobiotix strengthens US leadership team

    He has also served as vice president and head of clinical development oncology at MannKind, and held clinical leadership positions at MedImmune and Sigma-Tau Research.

  • Envigo appoints Patricia Henahan as chief financial officer Envigo appoints Patricia Henahan as chief financial officer

    Henahan brings 15 years of financial experience in the life science sector, including senior leadership roles at AstraZeneca, Eli Lilly and MedImmune.

  • Sanofi appoints Dr Yong-Jun Liu as head of research Sanofi appoints Dr Yong-Jun Liu as head of research

    Sanofi appoints Dr Yong-Jun Liu as head of research. He brings experience from MedImmune and the Baylor Research Institute. ... In January 2014, Dr Liu was appointed head of research at MedImmune, his most recent position.

More from appointments
Approximately 5 fully matching, plus 10 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

The Holy Grail of HCP Access
This is the data you need to gain access....
No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....

Infographics